国际眼科纵览

• 综述 • 上一篇    下一篇

内路黏小管成形术研究进展

范道青  钟华   

  1. 650032 昆明市,昆明医科大学第一附属医院眼科
  • 收稿日期:2017-03-13 出版日期:2017-06-29 发布日期:2017-06-29
  • 通讯作者: 钟华,Email: zhoculist@163.com
  • 基金资助:

     国家自然科学基金(81460085)

Research progress on ab interno canaloplasty

FAN Dao-qing, ZHONG Hua.   

  1. Department of Ophthalmology, 1st Affiliated Hospital of Kunming Medical University, Kunming 650032,China
  • Received:2017-03-13 Online:2017-06-29 Published:2017-06-29
  • Contact: ZHONG Hua,Email: zhoculist@163.com
  • Supported by:

    National Natural Science Foundation of China (81460085)

摘要:

黏小管成形术是在黏小管切开术基础上发展起来的一种新型Schlemm 管手术,通过扩张Schlemm 管重建自然房水外流通道,增加房水外流来降低眼压,避免了结膜瘢痕化及滤过泡相关并发症问题。黏小管成形术从最初的外路手术到近来改良的内路黏小管成形术(ab-interno canaloplasty,ABiC)变得更加微创、简单、标准化,在临床应用中取得了一定的效果;同时,不论是单独手术或是联合白内障手术,均显示出较好的安全性和有效性,具有较好的应用前景。本文对ABiC在临床应用的最新进展作一综述。(国际眼科纵览, 2017,  41:   187-191)

Abstract:

Canaloplasty is a non-penetrating surgical procedure to lower intraocular pressure in glaucoma without a fistula or need for a bleb. Its advantages over glaucomatous filtration surgery include absence of subconjunctival scar and bleb-related problems. Evolving directly from canaloplasty, ab-interno canaloplasty (ABiC) is a new minimally invasive glaucoma surgery (MIGS) procedure that can comprehensively restore the natural outflow pathways in patients with mild-to-moderate primary open angle glaucoma. Performed via a self-sealing, clear corneal incision, ab-interno approach, ABiC conserves the clinically proven benefits of 360° viscodilation of Schlemm’s canal by traditional canaloplasty. It uses breakthrough microcatheter technology to enlarge the trabecular meshwork , Schlemm’s canal and the collector channel system, improving outflow and lowering pressure. ABiC represents a truly minimally invasive, maximally effective and an excellent safety profile for reducing intraocular pressure as both a standalone procedure and when combined with cataract surgery. ABiC is also fast to perform and unlike other currently available MIGS procedures. ABiC preserves tissue and does not require the permanent placement of an implant in the eye. It has becoming a good prospect of application. (Int Rev Ophthalmol,  2017,  41:    187-191)